Original Article

Targeting the Interleukin-11 Receptor a in Metastatic Prostate
Cancer: A First-in-Man Study
 -Vila, PhD1,2;
Renata Pasqualini, PhD1,2; Randall E. Millikan, MD, PhD1,2‚Ä°; Dawn R. Christianson, PhD1,2; Marina Cardo
1,2
1,2
1,2
1,2
Wouter H. P. Driessen, PhD ; Ricardo J. Giordano, PhD ; Amin Hajitou, PhD ; Anh G. Hoang, MS ; Sijin Wen, PhD3;
Kirstin F. Barnhart, DVM, PhD4; Wallace B. Baze, DVM, PhD4; Valerie D. Marcott, RN2; David H. Hawke, PhD5;
Kim-Anh Do, PhD3; Nora M. Navone, MD, PhD1; Eleni Efstathiou, MD, PhD1,2; Patricia Troncoso, MD5; Roy R. Lobb, PhD6;
Christopher J. Logothetis, MD1,2; and Wadih Arap, MD, PhD1,2

BACKGROUND: Receptors in tumor blood vessels are attractive targets for ligand-directed drug discovery and development. The
authors have worked systematically to map human endothelial receptors (‚Äúvascular zip codes‚Äù) within tumors through direct peptide
library selection in cancer patients. Previously, they selected a ligand-binding motif to the interleukin-11 receptor alpha (IL-11Ra) in the
human vasculature. METHODS: The authors generated a ligand-directed, peptidomimetic drug (bone metastasis-targeting peptidomimetic-11 [BMTP-11]) for IL-11Ra‚Äìbased human tumor vascular targeting. Preclinical studies (efficacy/toxicity) included evaluating
BMTP-11 in prostate cancer xenograft models, drug localization, targeted apoptotic effects, pharmacokinetic/pharmacodynamic analyses, and dose-range determination, including formal (good laboratory practice) toxicity across rodent and nonhuman primate species. The initial BMTP-11 clinical development also is reported based on a single-institution, open-label, first-in-class, first-in-man trial
(National Clinical Trials number NCT00872157) in patients with metastatic, castrate-resistant prostate cancer. RESULTS: BMTP-11 was
preclinically promising and, thus, was chosen for clinical development in patients. Limited numbers of patients who had castrateresistant prostate cancer with osteoblastic bone metastases were enrolled into a phase 0 trial with biology-driven endpoints. The
authors demonstrated biopsy-verified localization of BMTP-11 to tumors in the bone marrow and drug-induced apoptosis in all
patients. Moreover, the maximum tolerated dose was identified on a weekly schedule (20-30 mg/m2). Finally, a renal dose-limiting
toxicity was determined, namely, dose-dependent, reversible nephrotoxicity with proteinuria and casts involving increased serum creatinine. CONCLUSIONS: These biologic endpoints establish BMTP-11 as a targeted drug candidate in metastatic, castrate-resistant
prostate cancer. Within a larger discovery context, the current findings indicate that functional tumor vascular ligand-receptor targeting systems may be identified through direct combinatorial selection of peptide libraries in cancer patients. Cancer 2015;121:2411-21.
C 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article
V
under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
KEYWORDS: bone metastasis-targeting peptidomimetic-11, clinical trial, interleukin-11 receptor a, prostate cancer, vascular targeting.

The copyright line for this article was changed on July 21, 2015 after original publication.
Corresponding authors: Renata Pasqualini, PhD, MSC07-4025, 1 University of New Mexico, 1201 Camino de Salud NE, Albuquerque, NM 87131; Fax: (505) 9250768; rpasqual@salud.unm.edu; and Wadih Arap, MD, PhD, MSC07-4025, 1 University of New Mexico, 1201 Camino de Salud NE, Albuquerque, NM 87131; Fax:
(505) 925-0768; warap@salud.unm.edu
1
David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas; 2Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 3Department of Biostatistics, The University of Texas MD
Anderson Cancer Center, Houston, Texas; 4Department of Veterinary Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas; 5Department
of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 6Alvos Therapeutics, Arrowhead Research Corporation, Pasadena, California;

Renata Pasqualini‚Äôs current address: University of New Mexico Cancer Center, Albuquerque, New Mexico
Dawn R. Christianson‚Äôs current address: Arrowhead Research Corporation, Pasadena, California
Marina Card
o-Vila‚Äôs current address: University of New Mexico Cancer Center, Albuquerque, New Mexico
Wouter H. P. Driessen‚Äôs current address: iTheraMedical, Munich, Germany
Ricardo J. Giordano‚Äôs current address: Institute of Chemistry, University of S~
ao Paulo, S~
ao Paulo, Brazil
Amin Hajitou‚Äôs current address: Department of Medicine, Imperial College London, London, United Kingdom
Sijin Wen‚Äôs current address: School of Public Health, West Virginia University, Morgantown, West Virginia
Kirstin F. Barnhart‚Äôs current address: Abbott Laboratories, Green Oaks, Illinois
Wadih Arap‚Äôs current address: University of New Mexico Cancer Center, Albuquerque, New Mexico
We thank Erin Horne, Bih-Fang Pan, and Connie Sun for technical assistance.
The first 2 authors contributed equally to this work.
See editorial on pages 2296‚Äì9, this issue.
Additional Supporting Information may be found in the online version of this article.
DOI: 10.1002/cncr.29344, Received: September 9, 2014; Revised: December 15, 2014; Accepted: December 23, 2014, Published online April 1, 2015 in Wiley
Online Library (wileyonlinelibrary.com)

Cancer

July 15, 2015

2411

Original Article

INTRODUCTION
Several lines of evidence indicate that blood vessels from
tumors express unique receptors that act as vascular ‚Äúzip
codes‚Äù and can be targeted with ligands.1-3 Although the
identification of functional ligand receptors within the tumor vasculature is challenging, we recently demonstrated
that screening peptide libraries directly in humans enables
unbiased target identification.4-7 Nevertheless, whether these
targets can be translated into therapies remains unclear.
Treatment options for metastatic castrate-resistant
prostate cancer are limited, and the development of new
therapeutic approaches is urgently needed. We identified
a peptide motif (CGRRAGGSC) that binds to
interleukin-11 receptor alpha (IL-11Ra) in the tumor vascular endothelium by administering a phage library to a
brain-dead cancer patient.4-6 Human IL-11Ra was overexpressed and had expression profiles similar to those of
IL-11Ra and cluster of differentiation 31 (CD31 [also
called platelet endothelial cell adhesion molecule]), with
colocalization during tumor progression and metastases in
a large cohort of prostate cancer patients; specific drug
binding to IL-11Ra and dose-dependent apoptosis induction of prostate cancer cells8 is mediated through a
receptor-interacting site within IL-11.9 Independent
groups have confirmed this ligand-receptor system by
characterizing the binding of CGRRAGGSC.10,11
On the basis of these findings, we designed a liganddirected agent, bone metastasis-targeting peptidomimetic-11 (BMTP-11), which consists of the
CGRRAGGSC motif synthesized in tandem to D(KLAKLAK)2, an apoptosis-inducing motif that is active on cell
internalization and has been validated in preclinical models of cancer, obesity, and retinopathies.8,12-17
Here, we report preclinical studies of BMTP-11
across rodent and nonhuman primate species and a phase
0 BMTP-11 trial in patients with castrate-resistant prostate cancer. To our knowledge, this is the first-in-class,
first-in-man clinical trial to emerge from our longstanding human mapping project.4-7 Our findings
include selective BMTP-11 localization to human bone
metastasis and targeted tumor apoptosis induction, providing evidence of drug activity and tumor toxicity in
humans. These biologic endpoints establish BMTP-11 as
a targeted drug candidate against human prostate cancer
and support its further development.
MATERIALS AND METHODS
Detailed methods are described in the Supporting Experimental Procedures (see online supporting information). Preclinical efficacy studies in rodents, pharmacokinetic, safety/
2412

toxicology studies in nonhuman primates, and criteria for
patient entry followed the procedures described in the Supporting Methods (see online supporting information).
RESULTS
Preclinical Efficacy of BMTP-11 Against
Prostate Cancer Xenografts

To evaluate the efficacy of BMTP-11 in preclinical settings, 2 classic nude mouse models were chosen: a
prostate-specific antigen (PSA)-producing, androgendependent model (LNCaP-derived) and a non-PSAproducing, androgen-independent model (DU145derived).8 In a third experimental system, we selected the
bone-forming prostate cancer MDA-PCa-118b model,18
which forms osteoblastic lesions in severe combined
immunodeficient (SCID) mice and uniquely recapitulates human prostate cancer.
In pilot experiments, nude mice bearing DU145derived tumor xenografts received either BMTP-11 (515 mg/kg subcutaneously every other day; produced
under good manufacturing practice conditions) or saline
(controls) (Supporting Fig. 1; see online supporting information). The efficacy of BMTP-11 was assessed by measuring serial changes in tumor volume. Tumors were
reduced (P < .0001) relative to controls in nude mice that
received 10 to 15 mg/kg BMTP-11 (Supporting Fig. 1A;
see online supporting information), whereas lower
BMTP-11 doses were less effective (Supporting Fig.
1B,C; see online supporting information).
Next, we assessed the efficacy of BMTP-11 (10 mg/
kg once weekly) by either intravenous or subcutaneous
administration in DU145-derived (Fig. 1A-C) or
LNCaP-derived (Fig. 1D-F) tumor xenografts. Differences in either DU145-derived or LNCaP-derived tumor
volumes in treated nude mice (P < .0001) were observed
relative to controls and, the optimal dose of BMTP-11 in
tumor-bearing mice was determined at approximately
10 mg/kg per week.
Marked expression/localization of IL-11Ra was
observed in MDA-PCa-118b tumors18 but not in nonmalignant stroma (Fig. 1G). Heterogenous IL-11Ra expression was measured using quantitative x-rays to
substantiate the pretreatment cohort assignment of
tumor-bearing SCID mice using the bone-to-soft tissue
ratio within tumors (Fig. 1H,I). Intravenous BMTP-11
treatment (10 mg/kg weekly) had antitumor effects compared with controls (P < .0001) (Fig. 1J-L). The average
control-treated tumors increased by 235% (range, 62%520%); in contrast, the change in BMTP-11‚Äìtreated, tumor-bearing SCID mice was only 10.6% (range, 240%
Cancer

July 15, 2015

BMTP-11 Trial in Human Prostate Cancer/Pasqualini et al

Figure 1. The efficacy of bone metastasis-targeting peptidomimetic-11 (BMTP-11) was investigated in tumor-bearing, immunodeficient mouse models of prostate cancer. (A) DU145-derived, tumor-bearing nu/nu (nude) mice were treated with either BMTP-11
(10 mg/kg; n 5 10) or saline (control; n 5 10) intravenously through the tail vein once weekly for 4 weeks. Tumor growth was serially monitored, and tumor volumes were measured over time. Data shown are the means 6 standard error of the means (SEM).
(B) In a mixed-effects model, there was a significant difference over time in the average percentage change from baseline for tumor volume in the treated animals versus the control animals (P <.0001). (C) Tumor volumes on day zero (pretreatment) and on
day 28 (post-treatment) are illustrated. (D) LNCaP-derived, tumor-bearing nude mice were treated with either BMTP-11 (15 mg/
kg; n 5 4) or saline (control; n 5 4) intravenously 3 times weekly for 2 weeks. Tumor growth was serially monitored, and tumor volumes were measured over time. Data shown are the means 6 SEM. (E) In a mixed-effects model, there was a significant difference
over time in the average percentage change from baseline for tumor volume in the treated animals versus the control animals
(P <.0001). (F) Tumor volumes on day zero (pretreatment) and on day 28 (post-treatment) are illustrated. (G) (Top Right) The
expression of interleukin-11 receptor alpha (IL-11Ra) is observed in MDA-PCA-118b‚Äìimplanted tumors (T) relative to (Bottom Right)
an immunoglobulin G (IgG) isotype-negative control. The asterisk indicates bone. (Top Left) Anti-CD31 (cluster of differentiation
31 [also called platelet endothelial cell adhesion molecule]) and (Bottom Left) hematoxylin and eosin (H&E) stains also are shown.
(H) Severe combined immunodeficient (SCID) mice bearing MDA-PCA-118b‚Äìimplanted tumors were divided into equal pretreatment cohorts using x-ray imaging, and (I) the bone-to-tumor stroma ratio was quantified in each group using relative mean grayscale analysis before treatment was initiated. (J) MDA-PCA-118b tumor-bearing SCID mice were treated with either BMTP-11
(10 mg/kg; n 5 5) or saline (control; n 5 5) intravenously through the tail vein once weekly for 3 weeks. Tumor growth was serially
monitored, and volumes were measured over time. Data shown are the means 6 SEM. (K) In a mixed-effects model, there was a
significant difference over time in the average percentage change from baseline for tumor volume in the treated animals versus
the control animals (P <.0001). (L) Tumor volumes on day zero (pretreatment) and on day 21 (post-treatment) are illustrated.

to 74.3%), thus indicating nearly complete growth suppression (Fig. 1K).
BMTP-11 Tissue Distribution

To evaluate BMTP-11 tissue distribution, polyclonal
antibodies (immunoglobulin G [IgG] antibodies [IgGs])
against the BMTP-11 proapoptotic domain were produced in rabbits using a single D(KLAKLAK) peptide
Cancer

July 15, 2015

(Supporting Fig. 2A; see online supporting information).
The antibody revealed anti-BMTP-11 immunoreactivity
as well as immunoreactivity to 2 other positive controls
(Supporting Fig. 2B; see online supporting information),
whereas there was no immunoreactivity against a negative
control peptide (Supporting Fig. 2C; see online supporting information). Affinity-purified anti-D(KLAKLAK)
IgGs detected BMTP-11 in a concentration-dependent
2413

Original Article

Figure 2. Bone metastasis-targeting peptidomimetic-11 (BMTP-11) pharmacokinetics and metabolites in nonhuman primates are
illustrated, including (A) the BMTP-11 standard curve in the plasma of cynomolgus monkeys and (B) the BMTP-11 plasma concentration time curves after intravenous infusion of BMTP-11 (at doses of 1 mg/kg, 3 mg/kg, and 9 mg/kg) for 2 hours. (C) This is a doselinearity plot for the 3 different BMTP-11 doses. AUC indicates the area under the plasma concentration-time curve. (D) Observed
values and model prediction fitted to a 1-compartment, open-body model (constructed using Phoenix WinNonlin [Certara LP,
Princeton, NJ]) are shown. (E) Identified metabolites of BMTP-11 in plasma and their predicted amino acid sequence were based on
molecular mass. The boxed top sequence indicates the parent drug, BMTP-11 (peak 2483 [p2483]). S-S indicates disulfide bonds.

manner (Supporting Fig. 2D; see online supporting information). BMTP-11 immunoreactivity was observed in
nontumor-bearing mice injected with BMTP-11
(25 mg/kg) into the kidneys 20 minutes postinjection
(Supporting Fig. 3A; see online supporting information)
and was restricted to the proximal tubules (Supporting
Fig. 3B; see online supporting information).
Next, BMTP-11 metabolism was analyzed in tissues
using matrix-assisted laser desorption/ionization time-offlight mass spectrometry19 (Supporting Fig. 4; see online
supporting information). Although the absolute concentration of each BMTP-11 metabolite could not be quantified unequivocally, the relative abundance of individually
identified metabolites was measured based on peak intensities relative to BMTP-11 and other internal standards.
Kidneys from mice injected with BMTP-11 revealed that
BMTP-11 disappearance correlated strongly with the
appearance of GG-D(KLAKLAK)2, G-D(KLAKLAK)2,
and D(KLAKLAK)2 metabolites (Supporting Fig. 4B; see
online supporting information). We observed that
D(KLAKLAK)2 was the predominant metabolite, and
there were no detectable levels of the parent compound or
metabolites containing any portion of CGRRAGGSC 4
2414

hours postadministration (Supporting Fig. 4C; see online
supporting information). These results indicate that the
immunoreactivity in the kidney sections may represent a
combination of the drug and its metabolic derivatives.
BMTP-11 Stability and Interaction

We established assays to evaluate BMTP-11 in vitro, in
vivo, and ex vivo. BMTP-11 stability in saline was determined by mass spectrometry. BMTP-11 was solubilized
and incubated either at room temperature or at 37 C, and
serial aliquots were analyzed. Spectra analyses revealed
only 2 major peaks, both corresponding to BMTP-11: the
first peak was the single-charged form, and the second
peak corresponded to the double-charged form (Supporting Fig. 5; see online supporting information). The latter
peak was not present in samples that were incubated for 8
to 24 hours, thus establishing that BMTP-11 is stable in
aqueous solutions (Supporting Fig. 5; see online supporting information). Finally, to evaluate the functional
attributes of BMTP-11 in a preclinical setting, bone marrow supernates from human prostate cancer specimens
were collected and incubated with the drug, and its activity against prostate cancer cells in vitro was unchanged
Cancer

July 15, 2015

BMTP-11 Trial in Human Prostate Cancer/Pasqualini et al

TABLE 1. Bone Metastasis-Targeting Peptidomimetic-11 Pharmacokinetic Parameters in Nonhuman
Primates
Estimate 6 SE
Pharmacokinetic
Parameter

BMTP-11
3 mg/kg

BMTP-11
9 mg/kg

Dose, mg
AUC, lg.h/mL
Clearance, liter/h
K10, 1/h
Half-life, h
Vd, liter
MRT, h

20.1
8.88 6 1.04
2.26 6 0.27
0.78 6 0.22
0.89 6 0.25
2.90 6 0.59
1.28 6 0.35

71.1
26.81 6 2.14
2.65 6 0.21
1.03 6 0.22
0.67 6 0.14
2.58 6 0.45
0.97 6 0.20

Abbreviations: AUC, area under the curve; BMTP-11, bone metastasistargeting peptidomimetic-11; K10, elimination rate constant; MRT, mean
residence time; SE, standard error; Vd, volume of distribution.

compared with BMTP-11 that was not pretreated (Supporting Fig. 6; see online supporting information).
BMTP-11 Pharmacokinetics in Rodents

To profile the biodistribution and pharmacokinetic properties of BMTP-11, first, we carried out pilot studies in
mice using 125I-BMTP-11 (Supporting Fig. 7; see online
supporting information). Mice received either 125IBMTP-11 (15 mg/kg intravenously) or phosphatebuffered saline, and blood samples were serially collected
postinjection. After 24 hours, the mice were killed, and
their organs were collected and analyzed using a cscintillation counter. This iodination strategy determined
a specific 125I-BMTP-11 activity of 0.27 millicuries per
gram. On the basis of a standard curve (Supporting Fig.
7A; see online supporting information), we estimated that
0.05% of the dose would constitute a good signal-to-noise
ratio (approximately 50-fold). Circulating 125I-labled
BMTP-11 levels dropped quickly, and, by 15 minutes
postinjection, only approximately 25% of the dose was
present in whole blood; radioactivity levels in whole blood
no longer decreased after 4 hours (Supporting Fig. 7B; see
online supporting information). After 24 hours, most of
the radioactivity was in the kidneys, liver, spleen, and
heart (Supporting Fig. 7C; see online supporting information). A pharmacokinetics profile was calculated using the
standard curve, and a noncompartmental analysis was performed (Supporting Table 1, Supporting Fig. 7D; see
online supporting information).
BMTP-11 Pharmacokinetics in Nonhuman
Primates

Next, we assessed the pharmacokinetics of BMTP-11 in
cynomolgus monkeys (Fig. 2, Supporting Fig. 8; see
Cancer

July 15, 2015

online supporting information). We detected BMTP-11
in plasma spiked with drug concentrations as low as 0.003
lg/mL (Supporting Fig. 8A,B; see online supporting information). Ratios between BMTP-11 and D(KLAKLAK)2, the internal standard (Supporting Fig. 8C; see
online supporting information), exhibited good linearity
(Fig. 2A), indicating that CGRRAGGSC did not alter the
stability of D(KLAKLAK)2. Cynomolgus monkeys
received intravenous infusions of BMTP-11 at doses of
1 mg/kg, 3 mg/kg, or 9 mg/kg over 2 hours to mimic the
intended clinical application. Plasma samples were collected over the course of 24 hours to generate plasma
concentration-time curves for each animal receiving each
dose (Fig. 2B). Our results indicated that BMTP-11 levels
increased during infusion and decreased exponentially to
background levels at 8 hours. The area under the curve
(AUC) from zero to infinity was calculated from each
plasma concentration-time curve. In the dose ranges evaluated, the AUC increased proportionally with increased
dose, indicating that BMTP-11 clearance mechanisms
were neither saturated (Fig. 2C) nor concentrationdependent. The data were best fitted to a 1-compartment
open-body model (Fig. 2D), and pharmacokinetic parameters were calculated (Table 1). The elimination rate constant for BMTP-11 was calculated using the terminal
portion of the plasma concentration-time curves. The
curve corresponding to the lowest BMTP-11 dose tested
(1 mg/kg) was not used, because samples that were collected 2 hours after the start of infusion (before discontinuing infusion) and 5 minutes postinfusion at this dose
were undetectable. Preliminary assessment of BMTP-11
metabolites in plasma from monkeys was based on their
molecular mass (Fig. 2E).
Dose-Range Determination and Toxicity Studies
in Rodents and Nonhuman Primates

Good laboratory practice (GLP) studies on mice, rats, and
monkeys were conducted to identify the dose range and
administration route for a formal assessment of the safety
of BMTP-11 (Supporting Table 2; see online supporting
information). Within the nonacute group (defined as the
group of animals in which >50% survived to study termination), renal injury, such as hyperplastic and/or regenerative lesions (as determined by clinical pathology and/or
gross necropsy), was the predominant toxicity, with
concentration-dependent severity observed across rodents
and primates. Clinical chemistry parameters related to renal function, such as serum creatinine and blood urea
nitrogen, often were elevated but generally returned to
baseline at the end of the study, indicating renal adaptive/
2415

Original Article
TABLE 2. Baseline Patient Demographics and Clinical Features by Bone Metastasis-Targeting Peptidomimetic-11 Dose
BMTP-11 Dose
18 mg/m2
Variable
Age at diagnosis, y
Age at trial registration, y
Interval from androgen deprivation to CRPC, y
Interval from CRPC to trial registration, mo
No. of prior cytotoxic therapies
Previous treatment with abiraterone
Serum PSA at registration
Serum alkaline phosphatase at trial registration
Hemoglobin at trial registration

Patient 1

Patient 2

36 mg/m2
Patient 3

62
74
5.3
78
2
Yes
2141
259
11.5

55
69
7.0
38
2
Yes
334
293
11.9

63
68
2.0
36
5
No
384
520
10.5

27 mg/m2
Patient 4

Patient 5

Patient 6

57
61
0.2
38
6
Yes
711
443
8.2

67
68
0.4
8
1
No
321
447
8.9

63
65
0.5
12
2
No
53
388
9.2

Abbreviations: BMTP-11, bone metastasis-targeting peptidomimetic-11; CRPC, castrate-resistant prostate cancer; PSA, prostate-specific antigen.

regenerative response. To rule out a neutralizing effect
contributing to transient renal findings, we measured serum levels of anti-BMTP-11 (antidrug antibodies) from
single-dose and multiple-dose studies in rodents and nonhuman primates (Supporting Fig. 9; see online supporting
information). Our results indicated that none of the mice
that received a single dose (3-10 mg/kg) and none of the
monkeys that received multiple BMTP-11 doses (4
weekly doses at 30 mg/kg per dose) developed immunoglobulin M (IgM) or IgG anti-BMTP-11 antibodies; serum samples collected from animals in these studies did
not exhibit immunoreactivity against BMTP-11 (Supporting Fig. 9A,B; see online supporting information).
Because CGRRAGGSC mimics native IL-11 binding to
IL-11Ra, which activates signal transducer and activator
of transcription 3 (STAT3),9 we measured serum anti-IL11 levels to ascertain whether there was a humoral immunogenic response against BMTP-11. Neither IgM nor
IgG was detected above background (Supporting Fig. 9C;
see online supporting information), indicating that
BMTP-11 is unlikely to induce a humoral response. Tumor toxicity results and the lack of an immunogenic
response led to a formal, definitive GLP safety assessment
study of BMTP-11 at doses of 1 mg/kg, 3 mg/kg, 6, and
9 mg/kg in nonhuman primates to complete preclinical
requirements for clinical trials.
Preclinical Safety of BMTP-11 in Nonhuman
Primates

A GLP-compliant safety study was carried out using cynomolgus monkeys to mimic the clinical regimen expected
(intravenous weekly for 4 doses). The objectives of this
nonclinical safety evaluation in primates were: 1) to iden2416

tify target organs for toxicity and determine whether toxicity was reversible, 2) to determine the starting dose and
dose-escalation, and 3) to identify parameters for safety
monitoring in humans. A recovery group at the highest
dose (9 mg/kg) was included. Clinical signs attributed to
BMTP-11 included alopecia, vomiting, dehydration,
increased urine output, and erythema. These clinical signs
were dose-dependent and were observed at the highest
doses (6 mg/kg and 9 mg/kg).
Hematologic findings included mild leukocytosis,
anemia, and mild thrombocytopenia. Mild-to-marked
azotemia was noted 1 week after the initial BMTP-11
dose. Azotemia lessened with continued administration
and was completely resolved at the end of the recovery period, with the exception of 2 of 3 monkeys in the highest
dose group.
Alterations in urinary analytes included glucosuria,
proteinuria, leukocyturia, and increased transitional/renal
epithelial cells. The magnitude of proteinuria and cell
counts in the urine decreased with continued drug administration; most urinary abnormalities resolved by the end
of the recovery period.
Primate necropsies 24 hours after the final BMTP11 infusion revealed dose-dependent findings primarily in
the monkeys that had received 3 to 9 mg/kg. Pale discoloration of the kidneys was grossly consistent with nephrosis. Kidney weights increased at the highest BMTP-11
dose. Histologic lesions were identified in the kidneys,
stomach, and pancreas and at infusion sites. Similar
dose-dependent lesions were described as degenerative/
necrotic, regenerative/reparative, and fibrotic and
were reported for BMTP-78,14 adipotide,17 and other
D(KLAKLAK)2-containing peptidomimetics. Tubular
Cancer

July 15, 2015

BMTP-11 Trial in Human Prostate Cancer/Pasqualini et al

Figure 3. Photomicrographs illustrate the expression of interleukin-11 receptor alpha (IL-11Ra) and negative control (immunoglobulin G [IgG] isotype) in human bone marrow. Each patient from the treated cohort (n 5 6) underwent a bone marrow biopsy
before receiving bone metastasis-targeting peptidomimetic-11.

necrosis and regeneration were noted in monkeys that had
received BMTP-11 at any dose; however, these findings
were graded minimal-to-mild at the 2 lowest dose levels,
and mild-to-moderate fibroplasia was observed only at
the 2 highest dose levels.
Additional preclinical safety GLP studies were performed using a large cohort (n 5 50) of primates (rhesus
and cynomolgus monkeys) with D(KLAKLAK)2-containing drugs.14,17 Details on some multiple-dose studies have
been reported.17 No lethality resulted from dosedependent toxicity in monkeys that received single
BMTP-11 doses up to 100 mg/kg. Preclinical safety studies identified renal tubules as the primary nontarget tissue
for adverse events, with no irreversible toxicity encounCancer

July 15, 2015

tered at the highest repeated doses tested. In the absence
of an identified lethal dose, we proposed an allometrically
estimated dose of 18 mg/m2 in humans, corresponding to
a BMTP-11 dose equivalent to 1.5 mg/kg in cynomolgus
monkeys,20 as a conservative starting dose for a first-inman clinical trial among castrate-resistant prostate cancer
patients with high-volume osseous metastasis. This starting dose is equivalent to only 5% of the dose level associated with reversible renal toxicity in monkeys.
BMTP-11 Clinical Trial

The first-in-man study (NCT00872157; available
at: http://clinicaltrials.gov/ct2/show/NCT00872157; accessed February 26, 2015) was designed to document ligand2417

Original Article

Figure 4. Bone metastasis-targeting peptidomimetic-11 (BMTP-11) targets bone metastasis in patients with castrate-resistant
prostate cancer. (A) This is the scheme for the first-in-man clinical trial design. GLP indicates good laboratory practice; IVPB, intravenous piggy-back infusion. (B) BMTP-11 detection by mass spectrometry is illustrated, including (Left) the cleaved proapoptotic domain and (Right) the parent BMTP-11 compound. (C) BMTP-11 immunocolocalization and (D) the terminal
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay are shown before and after treatment with BMTP-11 (18 mg/
m2) in representative patient samples.

directed targeting of BMTP-11 and to evaluate a correlation
of dose to activity and toxicity that would support a larger
dose-selection trial. A patient cohort (n 5 10) was identified
and screened in the trial with ‚Äúintent-to-treat.‚Äù During preenrollment screening, 4 patients were deemed noneligible
for trial entry because of a low hemoglobin level (n 5 1) or
an absence of tumor metastases upon bone marrow biopsy
(n 5 3). The remaining patients (n 5 6) were enrolled in a
dose-escalation cohort and received BMTP-11 starting at
18 mg/m2 intravenously weekly for 4 doses. All 6 enrolled
patients had high-volume, castrate-resistant bone metastases
for which no standard therapy options were available (Table
2). Patients had received a median of 2 previous chemotherapy regimens (range, 1-7 previous regimens), and 3 patients
(50%) had received systemic radionuclide-based therapy.
All patients had readily demonstrated biopsy-proven prostate cancer in bone before registration and underwent a
repeat biopsy within 2 to 4 hours after the first BMTP-11
dose. All patients entered in this study had baseline IL-11Ra
expression relative to a negative control IgG (Fig. 3).
Our trial required post-treatment bone metastasis
biopsies for BMTP-11 drug localization (Fig. 4A).
Patients 1 and 2 were treated at the lowest dose level
(18 mg/m2), and each received all 4 planned BMTP-11
doses with no clinically apparent toxicity despite mild
increases in serum creatinine, dipstick proteinuria, and
urinary casts. Patient 3 was treated at the highest dose level
(36 mg/m2) and had a grade 3 decrease in glomerular filtration: his serum creatinine level decreased from 0.7 mg/
2418

dL at baseline to 3.8 mg/dL on day 15. Consequently, he
received only 2 BMTP-11 doses. The protocol was then
modified to require more aggressive post-BMTP-11‚Äì
forced diuresis and was reopened afterward at an intermediate dose level (27 mg/m2). Three patients were subsequently treated at the 27 mg/m2 dose. Patient 4
completed the 4 planned doses with minimal renal toxicity. Patient 5 went off study after 2 doses because of disease progression: on day 15, his serum creatinine
increased from a baseline of 0.6 mg/dL to 1.3 mg/dL, and
his urine protein increased from 151 mg/24 hours to
1840 mg/24 hours. Patient 6 received 3 BMTP-11 doses
and came off study on day 22 because his urine protein
increased from 132 mg/24 hours to 2180 mg/24 hours.
A secondary objective was to define acute toxicity in
patients. There were no treatment-related deaths and no
grade 4 events. All grade 2 adverse events according to
National Cancer Institute criteria21 were included regardless of attribution (Table 3). Most of the events (anemia,
elevated alkaline phosphatase, and hypoalbuminemia)
reflected metastatic prostate cancer affecting bone. Two
patients (33%) came off study for dose-limiting renal toxicity. Consistently, proteinuria and increased serum creatinine levels were the most prominent toxicities identified
in the formal preclinical evaluation of BMTP-11 in
rodents and nonhuman primates.
BMTP-11 localization in treated patients was determined by mass spectrometry analyses (Fig. 4B) and/or
immunohistochemistry (Fig. 4C). It is noteworthy that,
Cancer

July 15, 2015

BMTP-11 Trial in Human Prostate Cancer/Pasqualini et al

TABLE 3. Adverse Events
No. of Patientsa
Adverse Event
Proteinuria
Back pain
Pain, not otherwise specified
Low serum albumin
Alkaline phosphatase
Anemia
Constipation
Creatinine
Fatigue
Glomerular filtration rate
Hyperglycemia
Hyponatremia
Hypokalemia
Joint effusion
Depression

Grade 3

Grade 2

0
0
0
0
2
2
0
0
0
1
1
1
1
0
0

6
1
2
1
2
2
1
1
2
1
0
0
0
1
1

a

Values are the number of patients who had an adverse event of the indicated grade.

in all 6 patient biopsies (100%; 95% confidence interval,
54%-100%), BMTP-11 accumulated at bone metastasis
sites, indicating binding to prostate cancer after intravenous infusion and consistent with the preclinical data. An
analysis of all tissue samples by terminal deoxynucleotidyl
transferase dUTP nick-end labeling revealed tumor apoptosis and BMTP-11 colocalization (Fig. 4D).
With respect to clinical activity, we observed no
responses defined according to Prostate Cancer Working
Group 2 criteria.22 Moreover, a heavily pretreated patient
(Patient 4) (Table 2) who received treatment at the
27 mg/m2 dose level had marked symptomatic improvement and experienced transient, simultaneous declines in
serum PSA, alkaline phosphatase, and lactate dehydrogenase levels coincidentally during BMTP-11 treatment, but
his tumor progressed rapidly when the candidate drug was
discontinued (Fig. 5).
DISCUSSION
Although the biology of castrate-resistant prostate cancer
remains poorly understood, most patients have osteoblastic bone metastases. With the exception of bone-seeking
radiopharmaceuticals,23,24 the development of drugs targeting the bone metastasis tumor microenvironment has
lagged behind new hormonal agents,25-28 immunotherapy,29 and cytotoxics.30
The preclinical evaluation of BMTP-11 activity and
its translation into an early clinical application in patients
included targeted efficacy, the development of liganddirected drug-detection methodology, and safety/toxicology studies in rodents and primates. All of these data were
Cancer

July 15, 2015

used to design and conduct a first-in-man clinical trial.
The primary endpoints of the study in patients with prostate cancer were to document physical targeting of BMTP11 and to evaluate the relation of dose to toxicity and efficacy in humans that would support a full phase 1 trial.
The clinical dose-limiting toxicity was somewhat predictable from our preclinical tissue-distribution and GLP
safety/toxicology studies; weekly BMTP-11 administration
in the dose range studied was associated with renal toxicity.
Preclinical safety study alterations in serum biochemical
and urinary analytes were attributed primarily to nephrotoxicity and altered proximal tubular function, and minimal changes were identified in the animals that received
the lowest doses. Renal toxicity is attributable to the Denantiomer proapoptotic moiety. Our studies revealed that
the targeting moiety (composed of L amino acid residues
only) was no longer present in the plasma 4 hours postinjection. Thus, all targeted D(KLAKLAK)2 peptidomimetics
present a very similar toxicity profile regardless of the targeted receptor within selective tissues. Hypophosphatemia,
hypokalemia, hyponatremia, hypochloremia, and glucosuria were attributed to decreased reabsorption at the proximal tubule. Given the absence of glomerular lesions,
proteinuria also was considered a likely consequence of
decreased endocytic uptake in the proximal tubule.
In the first-in-man trial, all patients experienced
increased serum creatinine and proteinuria, usually with
casts, and these nephrotoxic changes precluded the delivery of a full cycle in 2 of 6 patients (33%). These changes
were largely reversible without intervention beyond drug
withdrawal, and no patient developed chronic renal dysfunction. No other clinical adverse events were observed.
It is noteworthy that we demonstrated selective
BMTP-11 localization in bone marrow involvement in 6
of 6 patients (100%) with prostate cancer. This observation leaves no doubt that BMTP-11 reliably binds to prostate cancer after infusion and is consistent with its original
identification in cancer patients.4-9 Furthermore, colocalization of tumor apoptosis and BMTP-11 in this setting
confirms the preclinical activity of this ligand-directed
drug candidate and other D(KLAKLAK)2-containing
agents reported in animal models.12-17 We hope that
future studies with lead-optimized linkers, specific blockers, new formulations, and dose or schedule changes may
mitigate the reversible kidney toxicity resulting from renal
proximal tubule uptake. Because no lesions were observed
in the glomeruli, we concluded that the toxicity was not
caused by renal clearance.
In summary, this limited phase 0 trial with biologydriven endpoints 1) demonstrates ligand-directed drug
2419

Original Article

Figure 5. Serial changes in serum tumor markers are illustrated in a patient before and after treatment with bone metastasistargeting peptidomimetic-11 (BMTP-11). Serum prostate-specific antigen (PSA), alkaline phosphatase (Alk. Phos.), and lactate dehydrogenase (LDH) levels are indicated. 5-FU indicates infusional 5-fluorouracil plus concomitant external-beam radiotherapy;
CVD, intravenous cyclophosphamide and vincristine plus oral dexamethasone; DES/Dex, oral diethylstilbestrol plus oral dexamethasone; G/S, gemcitabine intravenously plus oral sunitinib; KA/VE, oral ketoconazole plus doxorubicin intravenously alternating on a weekly basis with oral estramustine plus vinblastine intravenously; T/C, paclitaxel plus carboplatin intravenously every 3
weeks; T/S, docetaxel intravenously plus oral sunitinib; VP-16/CDDP, etoposide plus cisplatin intravenously every 3 weeks.

localization in human tumor samples‚Äîdata that validate
vascular targeting observations in preclinical models, 2)
narrows the dose-range and schedule for a formal phase 1
study, 3) defines the acute toxicity profile, and 4) suggests
the possibility for clinical activity in patients with prostate
cancer who have osteoblastic bone metastases. Despite our
very small patient cohort in a small first-in-man study,
anatomic localization has been clearly demonstrated, an
2420

upper limit on BMTP-11 dose has been established for
this initially used ‚Äúweekly 3 4‚Äù schedule, and hints of
drug efficacy have been observed. The current results provide justification for consideration of BMTP-11 as a targeted prototype drug against human prostate cancer and
for the exploration of lower doses and/or alternative
schedules to evaluate whether there might be a threshold
below which the renal toxicity is minimized or abrogated.
Cancer

July 15, 2015

BMTP-11 Trial in Human Prostate Cancer/Pasqualini et al

From a wider perspective, the translation from humanbased discovery to a first-in-man clinical trial provides an
integrated paradigm for streamlined targeted drug development in human cancer.
FUNDING SUPPORT
This work was supported by the Gillson-Longenbaugh Foundation,
the Marcus Foundation, the Prostate Cancer Foundation, and the
National Institutes of Health (CA140388).

CONFLICT OF INTEREST DISCLOSURES
At the time of the study, The University of Texas MD Anderson
Cancer Center and Drs. Pasqualini, Arap, and Lobb owned equity
stock in Alvos Therapeutics (Arrowhead Research Corporation,
Pasadena, Calif). Dr. Christianson is a full-time employee of
Arrowhead Research Corporation, which has licensed rights to
technologies described in this article. Dr. Logothetis reports grants,
personal fees, and nonfinancial support from Astellas, Novartis
Pharmaceuticals, Bristol-Myers Squibb, Johnson & Johnson, Excelixis, and Pfizer. Dr. Arap reports research sponsorship, including
grants, personal fees, and other support, from Arrowhead Research
Corporation and is a shareholder in the company; he also reports
personal fees and other support from Alvos Therapeutics, Ablaris
Therapeutics, and AAVP Biosystems and personal fees from AMP
Pharmaceuticals, Ceramide Therapeutics, APAvadis, and Merck; in
addition, he has a patient (8,846,859) with royalties paid to Arrowhead Research Corporation.

REFERENCES
1. Pasqualini R, Moeller BJ, Arap W. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Semin Thromb Hemost. 2010;36:343-351.
2. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene
delivery agents. Adv Drug Deliv Rev. 2006;58:1622-1654.
3. Ozawa MG, Zurita AJ, Dias-Neto E, et al. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed
pharmacodelivery systems. Trends Cardiovasc Med. 2008;18:126-132.
4. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the
human vasculature by phage display. Nat Med. 2002;8:121-127.
5. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and braindead participants. Hastings Cent Rep. 2003;33:20-26.
6. Pentz RD, Cohen CB, Wicclair M, et al. Ethics guidelines for
research with the recently dead. Nat Med. 2005;11:1145-1149.
7. Staquicini FI, Card
o-Vila M, Kolonin MG, et al. Vascular ligandreceptor mapping by direct combinatorial selection in cancer
patients. Proc Natl Acad Sci U S A. 2011;108:18637-18642.
8. Zurita AJ, Troncoso P, Card
o-Vila M, Logothetis CJ, Pasqualini R,
Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 2004;64:435-439.
9. Card
o-Vila M, Zurita AJ, Giordano RJ, et al. A ligand peptide motif
selected from a cancer patient is a receptor-interacting site within
human interleukin-11 [serial online]. PLoS One. 2008;3:e3452.
10. Gu C, Liu L, He Y, Jiang J, Yang Z, Wu Q. The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human
prostate cancer cells. Oncol Lett. 2012;4:443-449.

Cancer

July 15, 2015

11. Wang W, Ke S, Kwon S, et al. A new optical and nuclear duallabeled imaging agent targeting interleukin 11 receptor alpha-chain.
Bioconjug Chem. 2007;18:397-402.
12. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-1038.
13. Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate
for destruction through a vascular address. Proc Natl Acad Sci USA.
2002;99:1527-1531.
14. Arap MA, Lahdenranta J, Mintz PJ, et al. Cell surface expression of
the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004;6:275-284.
15. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of
obesity by targeted ablation of adipose tissue. Nat Med. 2004;10:625632.
16. Lewis VO, Ozawa MG, Deavers MT, et al. The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma:
consistent data from cell lines, orthotopic models, and human tumor
samples. Cancer Res. 2009;69:1995-1999.
17. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic
targeting fat causes weight loss and improved insulin resistance in
obese monkeys [serial online]. Sci Transl Med. 2011;3:108ra112.
18. Li ZG, Mathew P, Yang J, et al. Androgen receptor-negative human
prostate cancer cells induce osteogenesis through FGF9-mediated
mechanisms. J Clin Invest. 2008;118:2697-2710.
19. US Food and Drug Administration. Guidance for Industry Safety
Testing of Drug Metabolites. Available at: http://www.fda.gov/
SiteIndex/default.htm. Accessed February 26, 2015.
20. US Food and Drug Administration. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for
Therapeutics in Adult Healthy Volunteers. Available at: http://www.
fda.gov/SiteIndex/default.htm. Accessed February 26, 2015.
21. Cancer Therapy Evaluation Program, National Cancer Institute.
Protocol Development: CTCAE v4.0 Open Comment Period. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30. Accessed February 26, 2015.
22. Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate
levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
23. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of
Samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:2436-2442.
24. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis
CJ. Phase I study of concurrent weekly docetaxel and repeated
Samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:3319-3324.
25. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer.
Science. 2009;324:787-790.
26. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;
367:1187-1197.
27. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and
increased survival in metastatic prostate cancer. N Engl J Med. 2011;
364:1995-2005.
28. Reid AH, Attard G, Danila DC, et al. Significant and sustained
antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol.
2010;28:1489-1495.
29. Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB. Cancer
immunotherapy: a paradigm shift for prostate cancer treatment. Nat
Rev Urol. 2012;9:376-385.
30. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label
trial. Lancet. 2010;376:1147-1154.

2421

0000 Targeting the Interleukin-11 Receptor a in Metastatic Prostate Cancer: A First-in-Man Study
Renata Pasqualini, Randall E. Millikan, Dawn R. Christianson, Marina Cardo-Vila, Wouter H. P. Driessen, Ricardo J.
Giordano, Amin Hajitou, Anh G. Hoang, Sijin Wen, Kirstin F. Barnhart, Wallace B. Baze, Valerie D. Marcott, David
H. Hawke, Kim-Anh Do, Nora M. Navone, Eleni Efstathiou, Patricia Troncoso, Roy R. Lobb, Christopher J. Logothetis,
and Wadih Arap
The authors report on the development of a new ligand-directed peptidomimetic (termed bone metastasis-targeting
peptidomimetic-11) for interleukin-11 receptor-based human vascular targeting, including the translation from preclinical
studies to a first-in-class, first-in-man clinical trial in patients with metastatic, castrate-resistant prostate cancer.

